Fig. 2: Validation of androgen receptor splicing variant 7 (ARv7) as miR-361-3p target. | Cell Death & Disease

Fig. 2: Validation of androgen receptor splicing variant 7 (ARv7) as miR-361-3p target.

From: The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer

Fig. 2

a Sequence alignment of miR-361-3p to ARv7 3′UTR. b RIP analysis in CWR22Rv1 cells (22Rv1) reveals recruitment of ARv7 mRNA to microRNA ribonucleoprotein complex following immunoprecipitation against Ago2. IgG immunoprecipitation is used as a negative control. c Synthetic sense or antisense ARv7 3′UTR with biotin is mixed with the total RNA followed by detection of miR-361-3p in the pulldown. d The wild-type and mutated ARv7 3′UTR via deleting the miRNA-binding sites is separately used as control for (e) and (f). e, f Luciferase reporter assay reveals that expressing miR-361-3p suppresses ARv7 3′UTR luciferase activity in 22Rv1 cells (e) and C4-2 cells (f). The assays are repeated three times with each assay being performed in triplicate wells and similar results being obtained each time. Representative results are shown as mean ± SD. *P < 0.05.

Back to article page